BACKGROUND: The serine/threonine kinase Raf-1 is a major regulator of the mitogen activated protein kinase (MAPK) pathway, which has been associated with the progression of prostate cancer to the more advanced and androgen-independent disease. Cdc25A phosphatase has been implicated in the regulation of Raf-1 and the MAPK pathway. METHODS: We used a novel and potent Cdc25A inhibitor, 2,3-bis-[2-hydroxyethylsulfonyl]-[1,4] naphthoquinone (NSC 95397), and its congener (2-mercaptoethanol)-3-methyl-1, 4-naphthoquinone (NSC 672121) to study the role of Cdc25A on the MAPK pathway in human prostate cancer cells. RESULTS: We found Raf-1 physically interacted with Cdc25A in PC-3 and LNCap cells and inhibitors of Cdc25A induced both extracellular signal-regulated kinase (Erk) activation and Raf-1 tyrosine phosphorylation. NSC 95397 attenuated Cdc25A and Raf-1 interactions due to accelerated degradation of Cdc25A, which was mediated by proteasome degradation. The MAPK kinase (MEK) inhibitor U0126 completely inhibited Erk activation by NSC 95397 and NSC 672121. CONCLUSIONS: These results indicate Cdc25A phosphatase regulates Raf-1/MEK/Erk kinase activation in human prostate cancer cells. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: The serine/threonine kinase Raf-1 is a major regulator of the mitogen activated protein kinase (MAPK) pathway, which has been associated with the progression of prostate cancer to the more advanced and androgen-independent disease. Cdc25A phosphatase has been implicated in the regulation of Raf-1 and the MAPK pathway. METHODS: We used a novel and potent Cdc25A inhibitor, 2,3-bis-[2-hydroxyethylsulfonyl]-[1,4] naphthoquinone (NSC 95397), and its congener (2-mercaptoethanol)-3-methyl-1, 4-naphthoquinone (NSC 672121) to study the role of Cdc25A on the MAPK pathway in humanprostate cancer cells. RESULTS: We found Raf-1 physically interacted with Cdc25A in PC-3 and LNCap cells and inhibitors of Cdc25A induced both extracellular signal-regulated kinase (Erk) activation and Raf-1tyrosine phosphorylation. NSC 95397 attenuated Cdc25A and Raf-1 interactions due to accelerated degradation of Cdc25A, which was mediated by proteasome degradation. The MAPK kinase (MEK) inhibitor U0126 completely inhibited Erk activation by NSC 95397 and NSC 672121. CONCLUSIONS: These results indicate Cdc25A phosphatase regulates Raf-1/MEK/Erk kinase activation in humanprostate cancer cells. Copyright 2003 Wiley-Liss, Inc.
Authors: Vasiliy N Korotchenko; Manush Saydmohammed; Laura L Vollmer; Ahmet Bakan; Kyle Sheetz; Karl T Debiec; Kristina A Greene; Christine S Agliori; Ivet Bahar; Billy W Day; Andreas Vogt; Michael Tsang Journal: Chembiochem Date: 2014-06-06 Impact factor: 3.164
Authors: Tatyana V Masyuk; Brynn N Radtke; Angela J Stroope; Jesús M Banales; Anatoliy I Masyuk; Sergio A Gradilone; Gabriella Bedekovicsne Gajdos; Natasha Chandok; Jason L Bakeberg; Christopher J Ward; Erik L Ritman; Hiroaki Kiyokawa; Nicholas F LaRusso Journal: Gastroenterology Date: 2011-12-07 Impact factor: 22.682
Authors: Faris Farassati; Weihong Pan; Farnaz Yamoutpour; Susann Henke; Mark Piedra; Silke Frahm; Said Al-Tawil; Wells I Mangrum; Luis F Parada; Samuel D Rabkin; Robert L Martuza; Andreas Kurtz Journal: Am J Pathol Date: 2008-11-06 Impact factor: 4.307
Authors: Petr Solc; Adela Saskova; Vladimir Baran; Michal Kubelka; Richard M Schultz; Jan Motlik Journal: Dev Biol Date: 2008-03-04 Impact factor: 3.582
Authors: Olivia Perwitasari; Ana Claudia Torrecilhas; Xiuzhen Yan; Scott Johnson; Caleb White; S Mark Tompkins; Ralph A Tripp Journal: J Virol Date: 2013-10-09 Impact factor: 5.103
Authors: Navneet Kumar Dubey; Bou-Yue Peng; Chien-Min Lin; Peter D Wang; Joseph R Wang; Chun-Hao Chan; Hong-Jian Wei; Win-Ping Deng Journal: Int J Mol Sci Date: 2018-05-31 Impact factor: 5.923
Authors: Berta Canal; Ryo Fujisawa; Allison W McClure; Tom D Deegan; Mary Wu; Rachel Ulferts; Florian Weissmann; Lucy S Drury; Agustina P Bertolin; Jingkun Zeng; Rupert Beale; Michael Howell; Karim Labib; John F X Diffley Journal: Biochem J Date: 2021-07-16 Impact factor: 3.857